First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...

Milestone Pharmaceuticals (MIST) announced that the U.S. Food and Drug Administration, FDA, approved its first commercial product, CARDAMYST nasal ...

The US FDA has approved etripamil (Cardamyst) nasal spray for the self-administered treatment of acute symptomatic paroxysmal ...

The FDA has approved DAYBUE STIX, a new powder option for Rett syndrome that grows royalty streams. The post Neuren ...

PDUFA Target Date of December 13, 2025 for CARDAMYST (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential ...

Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight ...

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (SRPT). The milestone was ...

The projected fair value for Milestone Pharmaceuticals is US$4.13 based on 2 Stage Free Cash Flow to Equity Current share price of US$2.32 suggests Milestone Pharmaceuticals is potentially 44% ...

The pilot horizontal levee in Palo Alto will only absorb .1 million gallons of water out of the 20 million gallons of ...

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is among the hidden multibagger stocks to invest in. On Dec. 1, 2025, XERS ...

Square Pharmaceuticals has achieved a significant overseas milestone as its Kenya-based subsidiary reported an operating profit for the first time, less than two years after starting commercial ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead ...